X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with AJANTA PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs AJANTA PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA AJANTA PHARMA DISHMAN PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 25.1 27.7 90.5% View Chart
P/BV x 3.3 11.4 29.3% View Chart
Dividend Yield % 0.7 0.5 126.5%  

Financials

 DISHMAN PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
AJANTA PHARMA
Mar-16
DISHMAN PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs3741,720 21.8%   
Low Rs1291,103 11.7%   
Sales per share (Unadj.) Rs197.8194.6 101.6%  
Earnings per share (Unadj.) Rs21.245.2 46.9%  
Cash flow per share (Unadj.) Rs34.750.3 69.0%  
Dividends per share (Unadj.) Rs2.008.00 25.0%  
Dividend yield (eoy) %0.80.6 140.2%  
Book value per share (Unadj.) Rs179.9132.0 136.2%  
Shares outstanding (eoy) m80.6988.77 90.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.37.3 17.5%   
Avg P/E ratio x11.931.2 38.0%  
P/CF ratio (eoy) x7.228.1 25.8%  
Price / Book Value ratio x1.410.7 13.1%  
Dividend payout %9.417.7 53.3%   
Avg Mkt Cap Rs m20,306125,299 16.2%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,3552,570 208.4%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,96117,275 92.4%  
Other income Rs m265166 159.6%   
Total revenues Rs m16,22617,442 93.0%   
Gross profit Rs m4,1035,807 70.7%  
Depreciation Rs m1,091451 242.0%   
Interest Rs m94449 1,931.3%   
Profit before tax Rs m2,3345,474 42.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6241,460 42.7%   
Profit after tax Rs m1,7114,014 42.6%  
Gross profit margin %25.733.6 76.5%  
Effective tax rate %26.726.7 100.2%   
Net profit margin %10.723.2 46.1%  
BALANCE SHEET DATA
Current assets Rs m11,0187,639 144.2%   
Current liabilities Rs m9,5172,715 350.6%   
Net working cap to sales %9.428.5 33.0%  
Current ratio x1.22.8 41.1%  
Inventory Days Days11043 255.6%  
Debtors Days Days3579 44.3%  
Net fixed assets Rs m16,3046,914 235.8%   
Share capital Rs m161177 91.2%   
"Free" reserves Rs m12,90711,442 112.8%   
Net worth Rs m14,51611,721 123.8%   
Long term debt Rs m4,189149 2,817.4%   
Total assets Rs m29,80514,814 201.2%  
Interest coverage x3.5112.9 3.1%   
Debt to equity ratio x0.30 2,274.9%  
Sales to assets ratio x0.51.2 45.9%   
Return on assets %8.927.4 32.5%  
Return on equity %11.834.2 34.4%  
Return on capital %17.546.5 37.7%  
Exports to sales %24.855.1 44.9%   
Imports to sales %3.76.0 62.2%   
Exports (fob) Rs m3,9569,527 41.5%   
Imports (cif) Rs m5961,038 57.5%   
Fx inflow Rs m4,95210,422 47.5%   
Fx outflow Rs m6971,678 41.5%   
Net fx Rs m4,2558,744 48.7%   
CASH FLOW
From Operations Rs m2,7863,264 85.4%  
From Investments Rs m-1,529-2,093 73.1%  
From Financial Activity Rs m-941-1,186 79.4%  
Net Cashflow Rs m316-15 -2,137.8%  

Share Holding

Indian Promoters % 61.4 73.8 83.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 1.6 238.7%  
FIIs % 12.7 7.6 167.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 17.0 130.0%  
Shareholders   46,261 20,968 220.6%  
Pledged promoter(s) holding % 35.8 4.4 814.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ALEMBIC LTD  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SHASUN PHARMA  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Red; Realty Stocks Top Losers(Closing)

After opening the day in green, share markets in India witnessed volatile trading activity throughout the day and ended the day on a dull note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS